Clinical Trials Logo
  1. Home
  2. Osteoporosis
  3. NCT06395883
  4. Details
NCT06395883 Clinical Trial

Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease

Osteoporosis Clinical Trial

— BOOGIE  

Official title:
Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease - the BOOGIE Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT06395883
Other study ID # DS-00846
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date August 2024
Est. completion date June 2028

Study information
Verified date April 2024
Source Diakonhjemmet Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, whichmin turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment. There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 160
Est. completion date June 2028
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 25 Years to 90 Years
Eligibility Inclusion Criteria: - diagnosis of inflammatory rheumatic joint disease - indication of disease modifying treatment initiation with or without glucocorticoids OR - stable DMARD treatment with parenteral glucocorticoid injection Exclusion Criteria: - known osteoporosis or osteoporosis treatment - women during the transitory phase - oestrogen treatment - any fracture within the last year - chronic glucocorticoid treatment - glucocorticoid treatment within the last year prior to inclusion - active cancer - kidney failure

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Glucocorticoid Effect
Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.

Locations
Country Name City State
n/a

Sponsors (3)
Lead Sponsor Collaborator
Diakonhjemmet Hospital Hormone Laboratory, Aker University Hospital, Oslo, Norway, Vestre Viken Hospital Trust

Outcome
Type Measure Description Time frame Safety issue
Primary P1NP level 3 months after glucocorticoid termination P1NP in a blood sample august 2024 til december 2025
Secondary P1NP level 6 months after glucocorticoid termination P1NP in a blood sample august 2024 til december 2025
Secondary CTX1 level 3 and 6 months after glucocorticoid termination CTX1 in a blood sample august 2024 til december 2025
Secondary P1NP and CTX1 dynamic until 6 months after treatment of inflammation without glucocorticoids P1NP and CTX1 in a blood sample august 2024 til december 2025
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06287502 - Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis N/A
Completed NCT03822078 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women Phase 1
Recruiting NCT05845021 - Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04736693 - Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Not yet recruiting NCT06431867 - Primary Care Management of Osteoporosis in Older Women
Completed NCT02922478 - Role of Comorbidities in Chronic Heart Failure Study
Recruiting NCT02635022 - Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Active, not recruiting NCT02617303 - Prevention of Falls and Its Consequences in Elderly People N/A
Completed NCT02566655 - Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis Phase 1
Completed NCT03420716 - Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women N/A
Completed NCT02559648 - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Phase 2
Not yet recruiting NCT02223572 - Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture N/A
Unknown status NCT01913834 - Nasally and sc Administered Teriparatide in Healthy Volunteers Phase 1
Not yet recruiting NCT01854086 - Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday N/A
Completed NCT02003716 - DeFRA Questionnaire as an Anamnestic Form N/A
Completed NCT01757340 - Calorie Restriction With Leucine Supplementation N/A
Completed NCT01694784 - Understanding and Discouraging Overuse of Potentially Harmful Screening Tests N/A